|
Green Cross (綠十字 ) () is a biopharmaceutical company headquartered in Yongin, South Korea. Green Cross specializes in the development and commercialization of vaccines, plasma-derivatives, recombinant proteins, and therapeutic antibodies for use in the fields of oncology and infectious disease. Green Cross was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of medicine and medical supplies, etc. Green Cross notably developed "Hepavax B", the world’s 3rd Hepatitis B vaccine in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world’s 2nd varicella vaccine in 1995, "Greengene", the world’s 4th recombinant drug for hemophilia A and the world's second treatment of Hunter syndrome “Hunterase” in 2012. As part of Green Cross’s global strategies, there are two operations based in the overseas at the moment. GC China was established in Anhui Province, China and, has produced plasma derivative products. GC China has established a pharmaceutical wholesaler last year. GCAM was established in December 2009 to secure plasma supply and enter into the US market. The company, currently runs a total of 4 plasma centers (San Bernardino, Calexico, Sacramento, and Laredo), and collects 100,000 liters of plasma a year that meets FDA standards for facilities and quality and supplies it to Green Cross. GCAM will play a significant role for introducing Green Cross’s flagship products including IVIG in the US market in the near future.〔Greencross.com, ("History" )〕 ==Research & Development== Green Cross has invested 7-8% of its annual revenue in R&D, which is the highest level in the domestic market, and plans to gradually increase the ratio to over 10%. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Green Cross (South Korea)」の詳細全文を読む スポンサード リンク
|